Skip to main content

Table 2 Base-case results

From: Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China

Strategy

Total Cost

Total QALYs

Incremental cost

Incremental QALYs

ICER ($/QALY)

Chemotherapy

13,717.50

0.95

   

Sacituzumab govitecan

104,991.22

1.38

91,273.72

0.43

211,948.62

  1. Note: QALYs, quality-adjusted life years; ICER, incremental cost-effectiveness ratio
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us